Source: International Congress 2014 – ERS/JAMA lunchtime session: 2014 highlights



Rating:

Share or cite this content

Citations should be made in the following way:
E. Mortensen (Dallas, United States of America). Macrolide therapy for pneumonia: balancing benefits with cardiovascular risks. International Congress 2014 – ERS/JAMA lunchtime session: 2014 highlights

Member's Comments

No comment yet.

Related content which might interest you: Guideline-concordant therapy and outcomes in healthcare-associated pneumonia Source: Eur Respir J 2011; 38: 878-887 Year: 2011 Forecasting the risk of medicinal complications from the chemical therapy in patients with multi-resistant pulmonary tuberculosis Source: Annual Congress 2011 - Challenges in tuberculosis control Year: 2011 Statin therapy and reduced risk of pneumonia in elderly patients with diabetes Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia Year: 2006 Treatment failure of community-acquired pneumonia: risk factors and consequences Source: Annual Congress 2012 - PG17 Clinical failure of treatment of respiratory infections Year: 2012 Broad-spectrum antibiotic use and poor outcomes in community-onset pneumonia Source: International Congress 2018 – Improving the outcomes of community-acquired pneumonia Year: 2018 Whether there are pharmacoeconomic and other advantages of using procalcitonin-guide antibacterial treatment in patients with severe community-acquired pneumonia in developing countries? Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management Year: 2015 Immunomodulating therapy and the risk of severe pneumonia Source: Eur Respir J 2002; 20: Suppl. 38, 353s Year: 2002 Strategies for de-escalation of therapy in patients with hospital-acquired pneumonia Source: Eur Respir J 2007; 30: Suppl. 51, 408s Year: 2007 Inhaled drugs as risk factors for community-acquired pneumonia Source: Eur Respir J 2010; 36: 1080-1087 Year: 2010 Inhaled drugs as risk factors for community-acquired pneumonia Source: Annual Congress 2010 - The spectrum of lower respiratory tract infections: risk factors of poor outcome and diagnostic tools Year: 2010 Management of patients with asthma or COPD and cardiovascular disease: risks versus benefits Source: Eur Respir Monogr 2020; 88: 66-81 Year: 2020 CPAP therapy in OSA patients: The effects on healthcare use and medical costs related to cardio- and cerebrovascular diseases Source: Annual Congress 2012 - CPAP: beneficial effects on different aspects of health Year: 2012 Verifying the antibiotic selection algorithm in the new Japanese pneumonia guidelines - Is algorithm-discordant treatment associated with increased mortality of healthcare-associated pneumonia? Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit Year: 2018 Impact of macrolide therapy on mortality in severe sepsis caused by pneumonia Source: Eur Respir J 2009; 33: 521 Year: 2009 Antibiotic resistance and clinical outcomes: the CAPNETZ experience Source: Annual Congress 2006 - PG1 - Respiratory infections: pneumonia/antibiotic resistance and clinical outcome of lower respiratory tract infections Year: 2006 Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia Source: Eur Respir J 2011; 37: 1332-1339 Year: 2011 Recommendations on long-term antibiotics and mucolytics for prevention of exacerbations of COPD Source: International Congress 2017 – Treatment and prevention of COPD exacerbation Year: 2017 Is CRP-guided antibiotic treatment a safe way to reduce antibiotic use in severe hospitalised patients with exacerbations of COPD? Source: Eur Respir J, 54 (4) 1901405; 10.1183/13993003.01405-2019 Year: 2019 Is CRP-guided antibiotic treatment a safe way to reduce antibiotic use in severe hospitalised patients with exacerbations of COPD? Source: Eur Respir J, 54 (4) 1901597; 10.1183/13993003.01597-2019 Year: 2019 Active monitoring of adverse drug reactions to the use of beta-lactam antibiotics in the treatment of community-acquired pneumonia Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections Year: 2020